The authors of “Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern®” (Ophthalmology. 2021;128:P151-P192) would like to note the following corrections:

The following references should have been cited after reference 189 in the following sentence on P169: Other glaucoma medications include, alpha2 adrenergic agonists, parasympathomimetics, rho-kinase inhibitors, and topical and oral carbonic anhydrase inhibitors.188,189


Table 2: The 5th row and footnote should have appeared as follows (correction in boldface):

<table>
<thead>
<tr>
<th>Drug Classification</th>
<th>Agents</th>
<th>Methods of Action</th>
<th>IOP Reduction*</th>
<th>Potential Side Effects</th>
<th>Potential Contraindications</th>
<th>FDA Pregnancy Safety Category†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rho kinase inhibitors</td>
<td>Netarsudil</td>
<td>Increase trabecular outflow Decrease episcleral venous pressure Decrease aqueous production</td>
<td>15%-25%</td>
<td>• Conjunctival hyperemia • Corneal verticillata • Instillation site pain • Conjunctival hemorrhage • Keratitis</td>
<td>• None</td>
<td>–**</td>
</tr>
</tbody>
</table>